N-038
6β-Naltrexol solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H25NO4
化学文摘社编号:
分子量:
343.42
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
certified reference material
质量水平
表单
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
forensics and toxicology
包装形式
single component solution
储存温度
2-8°C
SMILES字符串
OC1=C(O2)C([C@]([C@@H]2[C@H](O)CC3)(CCN4CC5CC5)[C@]3(O)[C@H]4C6)=C6C=C1
InChI
1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15-,18+,19+,20-/m1/s1
InChI key
JLVNEHKORQFVQJ-PYIJOLGTSA-N
一般描述
6ß-Naltrexol is the primary urinary metabolite of Naltrexone, an opiate sold under the trade names Revia, Depade, and Vivitrol® and used primarily in the management of alcohol or opiate dependence. This analytical reference standard is appropriate for use in LC/MS or GC/MS applications from clinical toxicology and forensic analysis to urine drug testing.
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vivitrol is a registered trademark of Alkermes, Inc.
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes
储存分类代码
3 - Flammable liquids
WGK
WGK 1
闪点(°F)
49.5 °F - closed cup
闪点(°C)
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Ling-Di Yan et al.
Yao xue xue bao = Acta pharmaceutica Sinica, 44(7), 722-725 (2009-10-08)
The pharmacokinetics of 6beta-naltrexol (6beta-NOL) following single intramuscular administration and multiple intramuscular injection once per day for seven days was studied in 4 Beagle dogs. Plasma concentration of 6beta-NOL in dogs was analyzed by a combination of high performance liquid
Waleed O Farid et al.
PloS one, 7(12), e52812-e52812 (2013-01-10)
Naltrexone is not recommended during pregnancy. However, sustained-release naltrexone implant use in humans has resulted in cases of inadvertent foetal exposure. Here, we used clinically relevant dosing to examine the effects of maternally administered sustained-release naltrexone on the rat brain
Stan L Banks et al.
Pharmaceutical research, 25(7), 1677-1685 (2008-05-02)
The purpose of this investigation was to evaluate the in vitro microneedle (MN) enhanced percutaneous absorption of naltrexone hydrochloride salt (NTX x HCl) compared to naltrexone base (NTX) in hairless guinea pig skin (GP) and human abdominal skin. In a
Mary F Divin et al.
European journal of pharmacology, 583(1), 48-55 (2008-02-16)
It has been proposed that on chronic morphine treatment the micro-opioid receptor becomes constitutively active, and as a consequence, the opioid withdrawal response arises from a reduction in the level of this constitutively active receptor. In support of this, the
Janet Yancey-Wrona et al.
Pain medicine (Malden, Mass.), 12(12), 1727-1737 (2011-11-30)
Opioid-induced constipation is a frequent side effect of opioid pain therapy due to opioid effects on the enteric nervous system, including gastric emptying and fluid absorption. The current exploratory studies were conducted to determine whether the neutral opioid antagonist 6β-naltrexol
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持